Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4Other hematologic neoplasm 3Lymphoid 3Thoracic 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1

Interventions

Everolimus 5Sunitinib 4lutetium Lu 177 dotatate 2PM 01183 2Octreotide 2Doxorubicin 2trifluridine tipiracil drug combination 1telotristat ethyl 1repotrectinib 1pralsetinib 1pegfilgrastim 1pasireotide 1motesanib diphosphate 1epothilone B 1dactolisib 1copper dotatate CU-64 1batifiban 1avelumab 1alectinib 1Temozolomide 1TKM-080301 1Surveys and Questionnaires 1SNX-5422 1Referral and Consultation 1Radiomics 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Molecular Diagnostic Techniques 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × SNX-5422 × NET × Clear all
NCT02063958 2018-07-30

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Esanex Inc.

Phase 1 Completed
19 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡